Skip to content
Catalyst

PapersPMID:36358485

A Randomized Controlled Trial on Pleurotus eryngii Mushrooms with Antioxidant Compounds and Vitamin D2 in Managing Metabolic Disorders.

Antioxidants (Basel, Switzerland)2022The record ↗

  1. Finding, moderate evidencelowersInterleukin-6 concentration

What moved

1 findingHow to read these marks →
  • “IL-6 and oxLDL decreased in the intervention group after 3 months and remained unchanged in the control group, with the mean changes being significantly different between the two groups.”
    Study
    RCT
    Dose studied
    snack consumed daily for 3 months; 6 g per sachet (sachets per day not stated)
    Population
    100 metabolically unhealthy adults (aged 18-76) with metabolic disorders in Athens, randomised to the mushroom snack plus standard nutritional counseling or to counseling alone; the 3-month change in each arm was compared

Study record

Design
randomised controlled trial
Species
human
Population
Metabolically unhealthy adults aged 18 to 76 years with metabolic disorders, Athens, Greece; baked, UV-B-irradiated Pleurotus eryngii snack (vitamin D2 enriched) added to standard nutritional counseling
Participants
100
Comparator
no treatment
Duration
91 days
Endpoints measured
21